|
| |
AventisAventis is dedicated to improving life through the discovery and development of innovative pharmaceutical products.
We offer a range of patented prescription drugs to treat patients with serious diseases and have leading positions in a number of therapeutic areas, including respiratory/allergy, cardiology/thrombosis, oncology and diabetes. We are also world leaders in the areas of human vaccines and therapeutic proteins.
Aventis has two products with sales of more than € 1 billion and two additional products with sales of more than € 500 million that are fast approaching blockbuster status. Several other products have significant potential, and we are focusing our marketing and sales activities on this group of “strategic brands.”
Our pipeline is full with a number of therapeutic innovations in development, including compounds for the treatment of diabetes and cancer as well as respiratory and cardiovascular diseases. More than 5,000 scientists at sites in France, Germany, Japan and the United States are expanding our leading position in the discovery and development of new drugs.
Aventis is dedicated to creating and delivering products of unquestionable quality that enable people to live longer, healthier and more active lives. In this spirit, we encourage our employees to care for each other’s well being and protect the environment in all aspects of their lives. We are committed to the principles of sustainable development, which is demonstrated by our participation in the U.N. Global Compact.
Aventis was created through the December 1999 business combination of Hoechst and Rhône-Poulenc. We are transforming Aventis into a pure pharmaceutical company through the divestiture of the Aventis CropScience and Aventis Animal Nutrition businesses as well as the remaining industrial activities. Along with our pharmaceutical business, Aventis will retain a 50% stake in the animal health business Merial, a joint venture with Merck & Co. (accounted for using the equity method).
| Contact Details: |
| Cedex 9 |
| Strasbourg |
| FR |
| 67917 |
| United Kingdom |
| Tel: | +33-388-99-1100 |
| Fax: | 33 (0) 3 8899 1375 |
| Email: | Arvind.Sood@aventis.com |
| WWW: | www.aventis.com/
|
| |
Recent Publications by Aventis: |  |
Cannabis and the Course of Schizophrenia.
Engagement of CD40 on the surface of antigen-presenting cells (APC) has... | 3rd October, 2008
| Dr. Zullino receives or has received research support from the Swiss
| Am J Psychiatry. 2008 Oct;165(10):1357-1358.
DOI Direct Link |
Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy.
Renal fibrosis is the common histological feature of advanced glomerular... | 24th September, 2008
| *INSERM, Department of Renal and Cardiac Remodeling-Team 5, Toulouse,
| FASEB J. 2008 Sep 22.
DOI Direct Link |
Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein - impact of physiological and pharmacological effectors.
Glucokinase (GK) is a key enzyme of glucose metabolism in liver and... | 24th September, 2008
| Research and Development, Sanofi-Aventis Deutschland GmbH, Frankfurt am
| J Biol Chem. 2008 Sep 22.
DOI Direct Link |
Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.
OBJECTIVES: The Global Cardiometabolic Risk Profile in Patients with... | 23rd September, 2008
| aDepartment of Cardiology, Ullevaal Hospital, Norway bSanofi aventis,
| J Hypertens. 2008 Oct;26(10):2064-2070.
DOI Direct Link |
Coordinated regulation of esterification and lipolysis by palmitate, H(2)O(2) and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes.
Inhibition of lipolysis by palmitate, H(2)O(2) and the anti-diabetic... | 16th September, 2008
| Sanofi-Aventis Pharma, Frankfurt am Main, Germany.
| Eur J Pharmacol. 2008 Sep 3.
DOI Direct Link |
→View more Aventis research publications. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 277 individuals from Aventis using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 240 times since April 2007, the link to the organisation's website has been followed 43 times Recent Search Terms used to find this page: CB1 antagonist | . Search for more companies in Strasbourg Search for more companies in FR This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Aventis |
